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Abstract
Background: For winter 2003/2004 in Scotland, it was recommended that all those aged 65 and over be eligible to receive 23-
valent polysaccharide pneumococcal vaccine (23vPPV), which has been shown to be effective in reducing the risk of invasive
pneumococcal disease (IPD). We assessed the success of the vaccination programme by examining the age specific incidence
rates of IPD compared to four previous winter seasons and estimating vaccination effectiveness.
Methods: Winter season incidence rates of IPD for vaccine targeted (65 years and over) and non-targeted (0–4, 5–34, 35–49,
50–64) age bands were examined for the Scottish population in a retrospective cohort design for winter 2003/2004. Details of
all IPD cases were obtained from the central reference laboratory and population vaccine uptake information was estimated
from a GP sentinel practice network. Based on the preceding four winter seasons, standardised incidence ratios (SIR) for invasive
pneumococcal disease were determined by age-band and sex during winter 2003/2004. Vaccination effectiveness (VE) was
estimated using both screening and indirect cohort methods. Numbers needed to vaccinate were derived from VE results using
equivalent annual incidence estimates for winter 2003/2004.
Results: Overall vaccination effectiveness using the screening method (adjusted for age and sex) in those aged 65 and over was
61.7% (95%CI: 45.1, 73.2) which corresponded to a number needed to vaccinate of 5206 (95%CI: 4388, 7122) per IPD case
prevented. Estimated effectiveness for the same age group using the indirect cohort method was not significant at 51% (95%CI:
-278, 94). Reductions in the winter season incidence rate of IPD were highly significant for all those aged 75+: males SIR = 58.8
(95%CI: 41.6, 80.8); females SIR = 70.0 (95%CI: 55.1, 87.8). In the 65–74 years age-group, the reduction for females was
significant: SIR = 60.3 (95%CI: 39.3, 88.4), but not for males: SIR = 74.8 (95%CI: 50.8, 106.3). There was no significant protective
effect on mortality.
Conclusion: The introduction of 23vPPV for those aged 65 and over in Scotland during winter 2003/2004, was accompanied
with a reduction of around one third in the incidence of IPD in this age group. Vaccination effectiveness estimates were
comparable with those from other developed countries.
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Background
Streptococcus pneumoniae is one of the leading causes of
bacteraemia and meningitis in the United Kingdom and
in public health terms remains one of the most important
bacterial pathogens worldwide [1]. While the incidence of
invasive pneumococcal disease (IPD) is highest in very
young children, the elderly and persons with underlying
medical conditions are also at increased risk and mortality
is highest in these groups [2,3]. In developed countries in
particular, the combination of an aging population and
rising levels of pneumococcal resistance to commonly
used antibiotics have focused attention on preventative
vaccination [4].
The current pneumococcal polysaccharide vaccine
(23vPPV), which consists of 23 serotype antigens corre-
sponding to over 90% of all invasive disease isolates, has
been available since the early 1980's [5]. Its efficacy was
first established against pneumococcal pneumonia in ran-
domized controlled trials conducted amongst novice
gold-miners in South Africa [6]. The balance of the evi-
dence from a subsequent wealth of prospective and retro-
spective studies in immuno-competent older adults [7]
together with cost effectiveness evaluations in the US [8]
and Europe [9] tends to support the targeting of older age
groups for vaccination as a worthwhile and cost saving
intervention. The most recent Cochrane review also con-
cluded that 23vPPV was effective against IPD although the
evidence was not sufficient against pneumonia [10].
In winter 2003/2004, 23vPPV was recommended for all
those aged 65 and over in Scotland and promoted in par-
allel with an influenza vaccination programme for the
same age group [11]. This approach was at variance with
the phased three year introduction programme for ten
year age-bands (beginning with those aged 85 and over)
that was adopted in England and Wales and completed in
2005/2006. The experience seen in Scotland may there-
fore serve as an early indication of the UK wide impact of
the programme. Previous to the age targeted campaign,
23vPPV vaccine had only been recommended for all per-
sons over the age of two years who were at increased risk
of IPD due to any of the following underlying medical
conditions: asplenia or splenic dysfunction; chronic renal
disease or nephrotic syndrome; immunosuppression
resulting from disease or treatment; chronic heart disease;
chronic lung disease; chronic liver disease including cir-
rhosis and diabetes mellitus [12]. The two principal out-
come measures by which the impact of the vaccination
campaign was assessed in this evaluation were firstly the
extent to which there was a reduction in the expected win-
ter incidence of invasive disease in the target age-groups,
since this was the major rationale behind the policy and
secondly, the estimated vaccination effectiveness for those
age 65 and over. During the time period of this evalua-
tion, 23vPPV was the only population level age-targeted
intervention against pneumococcal disease in Scotland
since the 7-valent pneumococcal conjugate vaccine (Pre-
venar) was not introduced into the childhood vaccination
programme until September 2006 [13].
Methods
Study design, population and time period
The impact of the pneumococcal vaccination campaign in
winter 2003/2004 was evaluated using a retrospective
cohort design which looked at vaccination effectiveness
and the age-specific incidence of IPD. The principle out-
come measures were observed changes in the 2003/2004
winter season incidence rates of IPD in the vaccine tar-
geted population of those aged 65 and over (divided into
males and females aged 65–74 and 75 and over). For
comparison, the incidence rates of invasive disease in
younger age bands (0–4, 5–34, 35–49 and 50–64) were
also examined for the same winter season. Figure 1 gives
an overview of the study design and data sources.
IPD incidence
Reports of all pneumococcal laboratory isolates from
every diagnostic laboratory in Scotland are collated at
Health Protection Scotland (HPS). In an ongoing collab-
oration with the Scottish Meningococcus and Pneumo-
coccus Reference Laboratory (SMPRL), surveillance for
invasive pneumococcal disease (IPD) involves obtaining
laboratory confirmation, serotype identification and anti-
biotic resistance profiling for all blood and CSF isolates.
There were no changes in culture procedures or in the cri-
teria used by diagnostic laboratories to submit isolates
over the period of the study. Laboratory reports of pneu-
mococcal infection for the winter seasons (weeks 40 of
preceding year to week 20 of the following year) were
extracted from the national HPS database for 1999/2000;
2000/2001; 2001/2002; 2002/2003; 2003/2004. Total
IPD isolates (i.e.: blood and CSF) for these time periods
were used to derive winter season incidence rates by age-
band (0–4, 5–34, 35–49, 50–64, 65–74 and 75+) and sex.
For ease of comparison with other published studies,
crude annualised incidence rates were estimated by
assigning a two-thirds weighting to the winter season total
(according to the mean proportion of annual cases which
occur during weeks 40 to 20).
Population totals were obtained from the General Register
Office for Scotland Statistics Library [14], the midyear esti-
mates preceding each winter season being used as denom-
inators. To verify any continuing trends, incidence rates
for winter 2004/2005 were also determined. A Poisson
regression model, using the log (population) as an offset
variable was used to predict the expected number of cases
for winter season 2003/2004, from which were derived
standardised incidence ratios (SIR). The Poisson modelBMC Infectious Diseases 2008, 8:53 http://www.biomedcentral.com/1471-2334/8/53
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used data on the incidence rates of the four preceding win-
ter seasons and included the following terms: winter sea-
son (continuous variable), age group, sex and the
interaction term of sex and age. The 95% confidence inter-
val (CI) for the SIR was calculated using the error factor
and a Chi-square test was used to compare numbers of
observed and expected cases.
Vaccine uptake
Estimates of 23vPPV vaccine uptake in winter 2003/2004
across the whole population were assessed through a sen-
tinel surveillance network called the continuous morbid-
ity record (CMR), which covers a seven percent
representative sample of the Scottish population [15]. In
contrast, influenza vaccine uptake data is not dependent
on sample population projections, since it is based on
item of service returns collated by the information and
Study design and data sources Figure 1
Study design and data sources.
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statistics division of NHS Health Services Scotland [16].
For every patient with laboratory confirmed IPD in winter
2003/2004, the Scottish community health index (CHI)
[17] was used to obtain the details of their general medical
practitioner/family doctor (GP). A postal questionnaire
was then sent to confirm the patient's disease outcome,
age, vaccination status with respect to both pneumococcal
disease (ever vaccinated) and influenza (for the 2003/
2004 season) and the presence of any underlying medical
conditions deemed to present an increased risk of IPD
[12]. For deceased patients whose records were no longer
held within primary care, permission to access medical
notes was sought in writing from the respective NHS
boards (via Caldicott guardians). IPD cases were regarded
as true vaccine failures if the date of vaccination was at
least 14 days prior to the sample date, or the GP reply con-
firmed they had been vaccinated before the onset of their
illness. For ethical purposes the patient follow up work
was not classified as research, but as an evaluation of an
ongoing vaccination programme. Chi-square tests for pro-
portions were used to compare differences in 23vPPV
uptake between sexes and different risk groups.
Estimation of vaccination effectiveness
Estimates of vaccination effectiveness (VE) using the
screening method described by Farrington [18] were
derived by age-band (all 65+; 65–74 and all 75+) and sex
using CMR uptake data projected across the whole popu-
lation. Stratified estimates were obtained after separating
patients classified as very high risk (VHR) which incorpo-
rated asplenics and the severely immuno-compromised
(haematological malignancies and non-haematological
malignancies who are currently receiving cancer therapy).
VE results were also expressed as numbers needed to vac-
cinate per IPD case prevented. In addition, the indirect
cohort method [19], which compares the proportions of
pneumococcal infections caused by 23vPPV serotypes
between vaccinated and unvaccinated IPD cases, was also
used to obtain an estimate of VE. The method assumes
vaccinated persons to be at the same risk of non-vaccine
serotype infections as unvaccinated persons and cross-
reactivity was assumed for serotypes closely related to vac-
cine components (e.g. 6A, 15C). Since the cohort effec-
tively covers the whole Scottish population and survival
outcomes were available from follow up, the relative risk
of dying from pneumococcal disease could be calculated
according to vaccination status for the target age-groups.
An 'IPD related fatality' (i.e. most likely to have been a
result of the pneumococcal disease episode) was defined
as a case where death had been reported as the outcome
on receipt of the sample by SMPRL, or where death was
subsequently established to have occurred within 14 days
of sample date. Mortality within 14 days of first positive
blood sample corresponds to the time period adopted by
the International Pneumococcal Study Group in relation
to death from pneumococcal bacteraemia [20].
Results
IPD incidence in winter season 2003/2004
There were a total of 442 cases of IPD in Scotland during
the study period, 170 of which occurred in those aged 65
and over. These correspond to equivalent annual inci-
dence rates of 11.7 per 100,000 overall and 31.1 per
100,000 for the 65+ age group. For the model used to cal-
culate standardised incidence rates there was no reason to
reject the hypothesis that the Poisson regression and the
included terms fitted the data (goodness-of-fit test P =
0.679). In winter 2003/2004 the observed incidence of
IPD cases was significantly less than expected (on the
basis of trends over the preceding four winter seasons) for
the 65+ age group as a whole (34% reduction: SIR = 66.4;
95%CI: 56.8, 77.2) (Table 1). For specific age-bands
within the 65+ population, there was a significant reduc-
tion for the 75+ age group of both sexes (male SIR= 58.8;
95%CI: 41.6, 80.8 and female SIR = 70.0; 95%CI: 55.1,
87.8) and for females in the 65–74 age group (SIR = 60.3;
95%CI: 39.3, 88.4). Among vaccine targeted age bands,
the only reduction that did not achieve statistical signifi-
cance was for that males aged 65–74 (SIR = 74.8; 95% CI
= 50.8, 106.3).
Vaccine uptake
Vaccine uptake estimates for the general population as
obtained at the beginning of December 2003 from CMR
practices were 68.1% for males and 65.5% for females
(Table 2). This figure had altered little by the end of vacci-
nation uptake monitoring when the overall figure based
on returns from general practice was 65% [21]. Of the 145
65+ IPD cases for whom vaccination status was known,
63(43.4%) had received pneumococcal vaccine (34 out of
66 (51.5%) male cases and 29 out of 79 (36.7%) female
cases). The proportion of vaccine recipients among 65+
IPD cases was not significantly different between those
with or without respiratory disease (45% vs. 42.5%
respectively, p = 0.760); those with or without cardiovas-
cular disease (50% vs. 37.9%, p = 0.182) or those with or
without 'more than one risk factor' (46.1% vs. 42.3%, p =
0.823).
Vaccine uptake rates in the CMR sample population were
inversely associated with the SIRs for both men and
women (Figure 2). The significant reduction in the SIR
was only seen among vaccine targeted age groups with a
correspondingly high vaccine uptake. Out of a total of 448
isolates, 417 were successfully matched to patient details
through their community health index numbers and after
exclusion of non-retrievable and mismatched records,
396 (88.4%) were available for follow up. Of those
matched records, 348 were completed for vaccination sta-BMC Infectious Diseases 2008, 8:53 http://www.biomedcentral.com/1471-2334/8/53
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tus and for the presence of underlying risk factors includ-
ing 145 (87.9%) of the 65+ cases. Table 3 shows the
baseline statistics of completed records linked to patients
with regard to sex, age and proportion of VHR. Overall, 75
(21.6%) IPD cases had received pneumococcal vaccina-
tion, with date of vaccination known for 71 (94.7%). Of
these, 43 (60.6%) had received vaccine in 2003 or 2004.
Out of a total of 60 23vPPV vaccine recipients in patients
Table 1: IPD Standardised Incidence Ratios (SIR) for winter 2003/2004 by age-band and sex
Age group 
(years)
Observed 
cases
Expected
cases
SIR 95% CI Chi- 
square
test P-
value
Equivalent
annual
incidence
 rates/
100,000
65+
Males 69 106 65.2 50.7 – 82.6 <0.001** 30.85
Females 101 150 67.1 54.7 – 81.6 <0.001** 31.33
65+ All 170 256 66.4 56.8 – 77.2 <0.001** 31.13
Males
0–4 36 30 118.4 82.9 – 164.1 0.310 40.04
5–34 37 25 150.2 105.7 – 207.2 0.013* 5.79
35–49 37 39 95.0 66.8 – 131.1 0.757 9.98
50–64 42 44 95.8 69.0 – 129.56 0.780 14.03
65–74 31 41 74.8 50.8 – 106.3 0.105 22.74
75+ 38 65 58.8 41.6 – 80.8 <0.001** 43.49
Females
0–4 27 18 152.2 100.2 – 221.8 0.028 31.41
5–34 32 16 204.8 140.0 – 289.4 <0.001* 5.05
35–49 26 20 129.4 84.4 – 189.8 0.188 6.62
50–64 35 42 83.9 58.4 – 116.8 0.298 11.16
65–74 26 43 60.3 39.3 – 88.4 0.009** 15.74
75+ 75 107 70.0 55.1 – 87.8 0.002** 47.72
* Significant increase from expected incidence rate produced by mode.
** Significant decrease from expected incidence rate produced by model
Table 2: Percentage vaccine uptake by age-band and sex in CMR sample and IPD cases
CMR IPD
Age Male
% vaccine uptake (total 
number in group)
Female
% vaccine uptake (total 
number in group)
Male
% vaccine uptake (total 
number in group#)
Female
% vaccine uptake (total 
number in group#)
Age group (years)
0 – 4 0.3% (9,181) 0.2% (8,697) 7.7% (26) 5.3% (19)
5 – 34 0.8% (89,636) 0.9% (86,147) 8.0% (25) 5.6% (18)
35 – 49 2.7% (42,428) 3.0% (41,461) 4.5% (22) 3.7% (27)
50 – 64 9.9% (32,724) 10.5% (32,673) 9.4% (32) 2.9% (34)
65 – 74 66.7% (13.887) 65.3% (15,866) 53.8% (26) 42.3% (26)
75+ 70.5% (8,744) 65.7% (14,907) 50.0% (40) 34.0% (53)
All age 65+ years 68.1% (22,631) 65.5% (30,773) 51.5% (66) 36.7% (79)
Very high risk --
No 22.4% (161) 18.3% (164)
Yes 60.0% (10) 23.1% (13)
# Excluding unknown vaccination statusBMC Infectious Diseases 2008, 8:53 http://www.biomedcentral.com/1471-2334/8/53
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aged 65 or over, 52 (86.7%) had also received influenza
vaccine for the 2003/2004 winter season. Among IPD
patients, the percentage who had received vaccine in all
age groups was generally higher for males compared to
females (Table 2), although the difference was not statis-
tically significant (p = 0.180). A slightly higher vaccine
uptake for males aged 65+ was also evident in the CMR
sample population. For the 65+ population as a whole,
there was a steady increase in the uptake of influenza vac-
cine over the course of the study period, rising from
64.9% in winter 2001/2002 to 68.9% in 2002/2003 and
72.5% in 2003/2004 [16].
Vaccination effectiveness
The overall result obtained for crude vaccination effective-
ness (VE) for the 65+ age group was 64.2% (95% CI: 49.6,
74.5) and after adjustment for age and sex, the revised
estimate was 61.7% (95% CI: 45.1, 73.2). The adjusted
figure corresponds to a number needed to vaccinate
(NNV) to prevent one IPD case of 5206 (95%CI: 4388,
Standardised incidence ratios (SIR) for invasive pneumococcal disease in winter 2003/04 with 95%CI limits and correlation with  vaccine uptake rates# by age-band and sex Figure 2
Standardised incidence ratios (SIR) for invasive pneumococcal disease in winter 2003/04 with 95%CI limits and correlation with 
vaccine uptake rates# by age-band and sex.
   
#
Vaccine uptake rates were from CMR population sample.BMC Infectious Diseases 2008, 8:53 http://www.biomedcentral.com/1471-2334/8/53
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7122). Table 4 shows VE results with 95% confidence lim-
its for those aged 65+, 65–74 and 75+ by sex after the
exclusion of the VHR category. Sex differences in effective-
ness are apparent for the 65–74 age band at 64.6% for
females (95%CI: 21.1, 84.1) versus 41.0% (95%CI: -31.7,
73.6) for males, although these differences as well as effec-
tiveness in males were not statistically significant. Esti-
mated VE for the VHR subgroup who were aged 65 and
over was also not significant at 37% (95%CI: -80, 70). The
very low numbers of non-vaccine component strains in
IPD patients (five out of the six cases being in 65+
patients, three of whom were vaccinated) means that the
VE estimate by the indirect cohort method was associated
with a high range of uncertainty and did not reach statis-
tical significance (VE (65+) = 51% (95% CI:-278, 94).
Since the majority of IPD patients who had received pneu-
mococcal vaccine also received the current seasonal influ-
enza vaccine, patient numbers were insufficient to obtain
a reliable estimate of vaccination effectiveness for pneu-
mococcal vaccine alone.
Serotype analysis and vaccine failures
Serotype confirmation was obtained for 388 (98%) of the
396 IPD isolates received in winter 2003/2004. Of the 109
IPD cases aged 65+ for whom serotype was confirmed, 46
out of 48 (95.8%) of those vaccinated had 23vPPV strains
as did 56 out of the 57 (98.2%) who had not been vacci-
nated. Of the three non-vaccine serotypes, serotypes 16
and 31 were found in vaccinated cases and serotype 34 in
a non-vaccinated case. For the whole dataset of IPD cases,
71 could be described as 'true vaccine failures', nine of
whom were classified as being very high risk ('VHR', see
methods). A further 20 patients were known to have had
Table 4: Vaccination effectiveness in those age 65 years and over (excluding very high risk) with equivalent number needed to 
vaccinate (NNV) estimates
Group Number of 
vaccinated cases
Total number 
of cases
% Vaccination Effectiveness 
(95% CI)
Equivalent Number Needed to 
Vaccinate #(NNV) with 95% CI
Age 65+ years
All
Crude 57 135 64.2 (49.6, 74.5) -
Adjust 61.7 (45.1, 73.2) 5206 (4388, 7122)
(Age/Sex) 30 59 53.5 (22.5, 72.1) 6059 (4499, 14407)
Male 27 76 71.1 (53.7, 81.9) 9835 (3987, 5944)
Female
Age 65–74 years
All 23 49 54.4 (20.1, 74.0) 9724 (7148, 26317)
Male 13 24 41.0 (-31.7, 73.6) (10726) §
Female 10 25 64.6 (21.1, 84.1) 9835 (7554, 30110)
Age 75+ years
All 34 86 68.8 (52.0, 79.8) 3145 (2712, 4162)
Male 17 35 60.5 (23.3, 79.6) 3801 (2895, 9891)
Female 17 51 73.9 (53.3, 85.4) 2836 (2454, 3932)
* Vaccination effectiveness as determined by the screening method (see Methods)
# NNV: number needed to vaccinate to prevent one case (calculated as 1/attributable risk; based on equivalent annual incidence of IPD in 2003/
2004.
§Hypothetical value for NNV given non-significant test result
Table 3: Baseline characteristics of IPD cases linked to patient records
Description IPD Cases linked to 
patient records
Completed Follow-up (%) Vaccination status known 
(%)
With >1 Risk factor (%) *
Number of subjects 396 368 348 61
Male (%) 198 (50.0) 181 (49.2) 171 (49.1) 28 (45.9)
Aged 65 + years (%) 165 (41.7) 156 (42.4) 145 (41.7) 43 (70.5)
% VHR§ - 29 (7.9) 23 (6.6) -
* With >1 risk factor: more than one known risk factor for pneumococcal disease as set out in non-age dependent criteria to be eligible for 
polysaccharide vaccine [12].
§ VHR denotes IPD cases in the very high risk category – defined as asplenics and the severely immuno-compromised (haematological malignancies 
and non-haematological malignancies who are currently receiving cancer therapy).BMC Infectious Diseases 2008, 8:53 http://www.biomedcentral.com/1471-2334/8/53
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more than one risk factor and overall 26 of the 71
(36.6%) were aged over 80 yrs.
Vaccination and IPD survival
There were 70 IPD related fatalities overall, 50 of which
occurred in those aged 65 and over and in which vaccina-
tion status was obtained for 44. Omitting the six cases
without vaccination details, the crude case fatality rate in
the 65 plus age group was 27.0% for vaccinated patients
and 32.9% for those who had not been vaccinated. Based
on estimated population uptake data, this translated into
a NNV to prevent one IPD related fatality of 14810 (Table
5). Since the reduced risk of dying as a result of pneumo-
coccal vaccination was not statistically significant, the
NNV estimate can only be seen as hypothetical. Crude rel-
ative risk reductions by age-band and sex for those aged
65 and over (based on pneumococcal vaccination status
alone), ranged from 0.71 to 0.96 though none were statis-
tically significant. There was also no difference by sex or
age-band (65–74 versus 75+).
Discussion
The introduction of 23-valent pneumococcal polysaccha-
ride vaccine for those aged 65 and over in Scotland in win-
ter 2003/2004 was accompanied with a significantly
reduced burden of invasive disease for this age group and
an estimated VE comparable with results seen elsewhere
[22-24]. Although other studies have demonstrated the
effectiveness of this intervention in reducing the incidence
of IPD, high levels of chronic disease morbidity in Scot-
land [25] that are not simply confined to qualifying med-
ical conditions, meant that automatic assumptions about
the likely success of such a campaign were not possible at
the outset. Preliminary incidence data for winter 2004/
2005, showing a continued reduced incidence of IPD in
the 65+ population (equivalent annual incidence rate of
30.0/100,000 compared with 31.1 for winter 2003/2004),
is further testimony to the apparent success of the pro-
gramme. A marginal though inconclusive reduction in
mortality risk was also suggested for IPD cases aged over
65 who had been vaccinated, although this was not statis-
tically significant for the one winter season analysed here.
The NNV to prevent one case of IPD in this evaluation
(5206) is considerably lower than the recent Cochrane
review estimate of 20,000 although this was calculated for
a 55 years and over population where incidence would be
much lower and is also based on a 50% vaccine effective-
ness [10]. Since the NNV estimates given here also used
equivalent annual incidence rates after the implementa-
tion of the vaccine programme, they can be considered to
be conservative.
While invasive pneumococcal disease accounts for only a
small component of the morbidity from the pneumococ-
cus, it is at the more severe end of the clinical spectrum
and it is the outcome for which the evidence is strongest
in showing a protective effect from 23vPPV [26]. There is
also a lack of ambiguity about a laboratory isolate, which
is not the case for 'all cause pneumonia' or 'all cause mor-
tality' which have also been used as indicator outcomes
Table 5: Pneumococcal vaccination status and relative risk (RR) of mortality in patients aged 65 years and over
Group Total no. in group % Died RR Mortality (95% CI) 
Crude
RR (95% CI) adjusted for 
age group and gender
NNV§ to prevent 1 
death
All age 65+ years
No vaccine 82 32.9 1.00 1.00 14,810
Vaccine 63 28.6 0.86 (0.47, 1.56) 0.89 (0.49, 1.63)
Age group (years)
65–74
No vaccine 27 22.2 1.00 - 39,172
Vaccine 25 16.0 0.71 (0.20, 2.51)
75+
No vaccine 55 38.2 1.00 - 8,122
Vaccine 38 36.8 0.96 (0.49, 1.89)
Gender
Males
No vaccine 31 32.3 1.00 -
Vaccine 34 29.4 0.90 (0.38, 2.17)
Females
No vaccine 51 33.3 1.00 -
Vaccine 29 27.6 0.81 (0.35, 1.89)
§NNV: Number needed to vaccinate to prevent 1 death. Note: since the reduction in mortality risk was not significant, these are hypothetical 
estimates included only for comparison purposes.BMC Infectious Diseases 2008, 8:53 http://www.biomedcentral.com/1471-2334/8/53
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for assessing VE against pneumococcal infection [27].
Additionally since the major rationale for the pneumococ-
cal vaccination campaign was aimed at reducing invasive
disease and its associated mortality and burden on health
services, this was believed to be the most legitimate means
by which to evaluate the programme's success or failure.
Observational studies can be said to assess the effects of
health care interventions without influencing the care that
is provided or the patients who receive it [28]. When used
in the assessment of vaccination programmes therefore
they have high external validity and broad generalisabil-
ity. In addition a number of randomised trials which have
sought to assess the effectiveness of 23vPPV have been
insufficiently powered to detect real benefits and have
therefore proven inconclusive, particularly with respect to
rare outcomes such as IPD [29]. Non-randomised studies
such as the current evaluation are limited by the extent to
which there may be dissimilarities between vaccinated
and non-vaccinated persons, in both their likelihood of
receiving vaccination and in their subsequent care and fol-
low up. Our findings that IPD patients with respiratory
disease, cardiovascular disease or more than one underly-
ing chronic health condition were no more likely to have
received vaccine that those who did not, provides some
reassurance in this regard. Further reassurance can be
derived from the presumption that if vaccine recipients
are more likely to be in poorer health, then the reported
benefits in this study would be an underestimate rather
than an overestimate of VE.
There are benefits as well as drawbacks to the evaluation
of a pneumococcal vaccine campaign based on just a sin-
gle post-implementation winter season. While the effects
remain subject to between season variability according to
temperature, airborne pollutants and circulating respira-
tory viruses [30], the short time frame also minimises dif-
ferences in effect that may arise from changes in
circulating serotypes and variability in the duration of
antibody response, which has been acknowledged as a
problem in elderly vaccine recipients [31]. With respect to
circulating respiratory viruses, the retrospective inclusion
of all four previous winter seasons benefited from known
low levels of influenza (at or below seasonal baseline
based on GP 'flu-spotter' consultations) in each of those
seasons and during the 2003/2004 season of 23vPPV
implementation [32]. Marginal increases in influenza vac-
cination uptake over the study period are therefore
unlikely to have influenced the disease burden of IPD. The
fact that almost all vaccinated IPD patients also received
influenza vaccine however means that we cannot exclude
the possibility that there was some additive benefit of
both vaccines as has clearly been demonstrated by other
authors [33,34]. The one season post-implementation
study design may also yield an over-optimistic evaluation
of VE that is not likely to be sustainable, due to both
declining antibody levels and the increased likelihood
with time of encountering non-vaccine component sero-
types [35]. Additionally, the modest scale of the Scottish
population makes it feasible to centrally collate all cases
of invasive pneumococcal disease allowing for complete-
ness of reporting and comparability between different
years and winter seasons. Retrospective ascertainment of
vaccination status is of course less dependable than pro-
spective clarification, but the use of GP records is more
reliable than self-reporting methods [36] as is the elec-
tronic recording of uptake rates in the sample CMR popu-
lation.
In spite of our results being restricted to one winter sea-
son, it has been possible to derive VE values in those aged
65 and over that compare well with other studies that
have also looked at IPD prevention [23,37]. A high vac-
cine uptake in the first season of implementation also
means that any observed effect on the burden of disease is
not likely to be blurred by an annually increasing uptake
rate, as has been postulated for the US [38]. While sub-
stantial overlap between the confidence intervals makes it
difficult to interpret the variation in VE by sex and age-
band, the finding of the highest effectiveness being in the
75+ age category contrasts with the diminishing effective-
ness with age generally seen in other studies. For the Scot-
tish population however an element of survivor bias may
be relevant, since the majority of those surviving to 75+
years of age are from higher socio-economic groups [39].
The higher effectiveness in females aged between 65 and
74 in spite of lower vaccine uptake, may reflect higher lev-
els of underlying chronic illness in males of this age group
(although this is not evident from available risk factor
data in this study, Table 3). More severe underlying illness
has also been linked with an increasing the likelihood of
opting for vaccination [40]. A slightly higher uptake of the
pneumococcal plus flu vaccine in older males, which is a
combination known to have additive benefits [33], may
also have contributed to the high effectiveness in this sub-
group although, as noted previously, seasonal influenza
activity was low throughout the study period. The current
estimate of VE by the indirect cohort method is character-
ised by a high range of uncertainty although the actual
value of 51% for those aged 65+ is not incompatible with
a protective effect. The multiple infecting serotypes of the
pneumococcal pathogen together with the high valency of
23vPPV mean that reliable estimates using this method,
such as that derived by Butler in the US [41], commonly
require large numbers of cases (specifically around 2400
gathered over a period of 14 years in that particular
study). Single winter season estimates such as our own or
that determined in a recent Australian study [22] inevita-
bly have low numbers of rare non-vaccine serotypes
which introduces a large margin of error.BMC Infectious Diseases 2008, 8:53 http://www.biomedcentral.com/1471-2334/8/53
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The parallel targeting of pneumococcal vaccine with sea-
sonal influenza has been shown to be an effective means
of achieving high uptake in pneumococcal programmes
for older adults [42] and the estimated overall uptake lev-
els in the 65+ for the season under study (at 65%) also
reflect the suitability of primary care as a means of deliv-
ery. The recent Australian evaluation [22] reported reduc-
tions in IPD incidence (36%) of similar magnitude to that
seen in Scotland and VE estimates in the same range as for
the current study (71%: 95%CI: 54, 82). Similarly overall
VE estimates obtained from a case control study in Cata-
lonia [23] were also in the same range (65%: 95%CI: 35,
81). These comparisons add a measure of confidence to
the generalisability of our results to other developed
countries.
The inherent complexity of the pneumococcus and it's
sophistication in evading the host immune response,
requires that a high degree of vigilance at both the epide-
miological and microbiological levels continue to accom-
pany the ongoing implementation of this vaccine
programme for older adults. A key issue in its medium to
long term success will be the duration of protective effect
which several studies have shown to decline rapidly in
elderly subjects and in a manner that is not uniform across
all serotypes [27,35]. The extent to which the elderly pop-
ulation may have gained additional protection from the
introduction of 7-valent conjugate vaccine (PCV-7) to the
childhood schedule from September 2006 [13] mediated
through a herd immunity effect [43], and as has shown
promise in the US [44], awaits further investigation. Pro-
tection against invasive disease is of course only one
aspect of tackling pneumococcal morbidity and the extent
to which polysaccharide vaccine, either alone or in com-
bination with the new conjugate vaccines, might be able
to reduce pneumococcal pneumonia is the next key ques-
tion in tackling the societal burden of this pathogen. The
evidence with regard to pneumonia is certainly less clear
cut and may need to await the development of more spe-
cific and efficient diagnostic tests [45].
Conclusion
The introduction of pneumococcal polysaccharide vac-
cine for those aged 65 and over in Scotland during winter
2003/2004 was associated with a reduction of around one
third in the incidence of invasive pneumococcal disease in
this age group. Given the epidemiological diversity of the
pneumococcus by population and by region [4], policy-
makers ought to be encouraged that the VE estimates
obtained are comparable to those seen in other developed
countries. Additionally, as the first large scale demonstra-
tion of effectiveness in a UK population, the results
should strengthen the evidence base for health care prac-
titioners involved in distributing vaccine in England and
Wales, now that the phased roll-out to all over 65s is com-
plete. Joint influenza and pneumococcal immunization
in the primary healthcare setting is both effective and
widely acceptable as evidenced by high uptake rates, and
should continue to be a mainstay of disease prevention
for this age group in years to come. Whether the reduced
incidence of invasive disease will persist for those aged 65
and over will only be apparent when data for future years/
winter seasons are analysed. Of course any sustained
change in serotype distribution towards non-vaccine com-
ponent serotypes may yet have significant implications for
the current vaccination programme and its longer term
effectiveness.
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